— Know what they know.
Not Investment Advice

CRNX NASDAQ

Crinetics Pharmaceuticals, Inc.
1W: -3.2% 1M: -5.1% 3M: -14.6% YTD: -20.6% 1Y: +18.2% 3Y: +67.8% 5Y: +128.7%
$36.80
-0.29 (-0.78%)
 
Weekly Expected Move ±8.8%
$30 $34 $37 $40 $43
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 38 · $3.9B mcap · 98M float · 1.24% daily turnover · Short 62% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
47.9 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: -3385.4%  ·  5Y Avg: -677.8%
Cost Advantage
34
Intangibles
55
Switching Cost
47
Network Effect
82
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. CRNX shows a Weak competitive edge (47.9/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Network Effects. Negative ROIC of -3385.4% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$84
Low
$86
Avg Target
$88
High
Based on 2 analysts since May 7, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 18Hold: 0Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$86.00
Analysts2
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-15 Evercore ISI Gavin Clark-Gartner $90 $88 -2 +133.4% $37.71
2026-05-11 Oppenheimer $87 $84 -3 +122.3% $37.80
2026-01-30 Stifel Nicolaus $75 $84 +9 +60.2% $52.44
2026-01-12 Goldman Sachs Richard Law $36 $67 +31 +25.8% $53.25
2026-01-08 Morgan Stanley $77 $87 +10 +64.7% $52.82
2026-01-08 China Renaissance Securities (US) Inc. Initiated $105 +96.9% $53.34
2026-01-05 Evercore ISI Initiated $90 +75.6% $51.26
2026-01-05 Stifel Nicolaus Alex Thompson $60 $75 +15 +48.3% $50.57
2025-09-30 Oppenheimer $74 $87 +13 +100.0% $43.51
2025-09-28 Morgan Stanley $70 $77 +7 +67.7% $45.91
2025-09-26 JMP Securities Jonathan Wolleben $91 $143 +52 +211.5% $45.91
2025-07-10 Goldman Sachs Richard Law Initiated $36 +12.5% $31.99
2025-03-24 Stifel Nicolaus Alex Thompson Initiated $60 +66.9% $35.94
2025-02-28 JMP Securities $80 $91 +11 +154.3% $35.78
2024-08-09 H.C. Wainwright Douglas Tsao Initiated $69 +36.0% $50.74
2024-06-04 Oppenheimer Leland Gershell $54 $74 +20 +59.9% $46.28
2024-05-23 Robert W. Baird Brian Skorney Initiated $62 +26.2% $49.13
2024-05-22 Morgan Stanley Jeffrey Hung Initiated $70 +38.5% $50.54
2024-05-07 Piper Sandler Yasmeen Rahimi Initiated $97 +104.3% $47.47
2024-03-19 JMP Securities Jonathan Wolleben Initiated $80 +75.9% $45.49
2024-03-13 Oppenheimer Leland Gershell $40 $54 +14 +33.3% $40.50
2023-08-31 Oppenheimer Leland Gershell Initiated $40 +129.5% $17.43
2022-05-26 Leerink Partners Initiated $39 +124.5% $17.37

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C-
May 22, 2026
DCF
1
ROE
1
ROA
1
D/E
3
P/E
1
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. CRNX receives an overall rating of C-. Areas of concern: DCF (1/5), ROE (1/5), ROA (1/5), P/E (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-04-01 C C-
2026-03-30 C- C
2026-02-24 C C-
2026-02-19 C- C
2026-02-17 C C-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

39 Grade D
Profitability
20
Balance Sheet
84
Earnings Quality
66
Growth
52
Value
36
Momentum
50
Safety
100
Cash Flow
30
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. CRNX scores highest in Safety (100/100) and lowest in Profitability (20/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
13.52
Safe Zone
Piotroski F-Score
2/9
Beneish M-Score
26.13
Possible Manipulator
Ohlson O-Score
-3.54
Bankruptcy prob: 2.8%
Low Risk
Credit Rating
A+
Score: 75.6/100
Trend: Stable
Earnings Quality
OCF/NI: 0.83x
Accruals: -6.4%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. CRNX scores 13.52, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. CRNX scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. CRNX's score of 26.13 exceeds the −1.78 red flag threshold — this does not confirm manipulation but indicates the earnings profile resembles past manipulators statistically. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. CRNX's implied 2.8% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. CRNX receives an estimated rating of A+ (score: 75.6/100), with a stable trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-7.72x
PEG
0.28x
P/S
214.74x
P/B
2.99x
P/FCF
-9.01x
P/OCF
EV/EBITDA
-5.17x
EV/Revenue
155.05x
EV/EBIT
-5.13x
EV/FCF
-6.68x
Earnings Yield
-13.13%
FCF Yield
-11.10%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. CRNX currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
0.909
EBT / EBIT
×
EBIT Margin
-30.203
EBIT / Rev
×
Asset Turnover
0.014
Rev / Assets
×
Equity Multiplier
1.109
Assets / Equity
=
ROE
-42.8%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. CRNX's ROE of -42.8% is driven by Asset Turnover (0.014), indicating efficient use of assets to generate revenue. A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$36.80
Median 1Y
$32.53
5th Pctile
$11.93
95th Pctile
$88.21
Ann. Volatility
62.7%
Analyst Target
$86.00
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
R. Scott Struthers,
Ph.D. President and Chief Executive Officer
$718,500 $3,280,540 $11,628,959
Tobin Schilke Financial
ancial Officer
$452,250 $1,755,000 $4,357,893
Dana Pizzuti, M.D.
Chief Medical and Development Officer
$573,333 $1,584,980 $3,910,331
Stephen F. Betz,
Ph.D. Chief Scientific Officer
$520,000 $1,584,980 $3,827,148
Jeff Knight Operating
rating Officer
$511,667 $1,584,980 $3,826,671
Marc Wilson Financial
ief Financial Officer
$119,788 $514,620 $3,255,392

CEO Pay Ratio

2188:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $11,628,959
Avg Employee Cost (SGA/emp): $5,315
Employees: 36,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
36,000
+8138.0% YoY
Revenue / Employee
$214
Rev: $7,696,000
Profit / Employee
$-12,925
NI: $-465,317,000
SGA / Employee
$5,315
Avg labor cost proxy
R&D / Employee
$9,224
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE -62.2% -68.9% -43.0% -47.7% -54.2% -59.8% -50.6% -54.1% -56.7% -61.5% -50.2% -55.1% -60.4% -65.0% -32.0% -35.2% -39.7% -45.4% -40.2% -42.8% -42.85%
ROA -56.7% -62.8% -40.3% -44.7% -50.8% -56.0% -46.6% -49.9% -52.3% -56.7% -43.4% -47.7% -52.4% -56.3% -28.8% -31.7% -35.7% -40.9% -36.2% -38.6% -38.63%
ROIC -34.3% -37.9% -64.9% -71.5% -81.7% -91.1% 8.8% 9.6% 10.1% 10.9% -5.4% -6.1% -6.8% -7.5% -11.9% -13.3% -14.9% -16.8% -32.1% -33.9% -33.85%
ROCE -51.6% -57.0% -32.1% -35.4% -40.5% -45.1% -51.7% -56.1% -59.2% -64.0% -37.6% -42.0% -47.0% -51.9% -24.6% -27.4% -30.8% -34.8% -49.2% -52.0% -51.95%
Gross Margin -21.8% -8.0% -74.2% -68.8% -51.2% -13.4% -40.1% -125.7% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 98.1% 98.14%
Operating Margin -28.7% -10.8% -98.1% -94.9% -67.1% -17.9% -53.6% -170.5% -114.9% -207.5% -308.6% -125.2% -997.1% -21.7% -13.1% -13.08%
Net Margin -28.6% -11.1% -96.5% -91.5% -63.5% -17.2% -51.6% -166.1% -104.6% -185.6% -268.1% -112.2% -909.7% -19.9% -11.9% -11.91%
EBITDA Margin -28.4% -10.7% -97.6% -94.3% -66.7% -17.8% -53.4% -169.7% -114.1% -205.6% -306.0% -124.3% -990.0% -21.5% -13.0% -12.97%
FCF Margin -82.6% -19.6% -19.6% -20.4% -24.7% -33.6% -33.4% -35.4% -42.6% -93.4% -135.1% -195.9% -221.2% -349.1% -219.7% -231.9% -49.9% -23.2% -23.22%
OCF Margin -82.2% -19.5% -19.4% -20.2% -24.3% -33.2% -33.1% -34.5% -41.4% -90.4% -130.2% -192.3% -217.5% -344.2% -215.4% -227.8% -49.1% -22.9% -22.92%
ROE 3Y Avg snapshot only -39.50%
ROE 5Y Avg snapshot only -41.97%
ROA 3Y Avg snapshot only -34.55%
ROIC Economic snapshot only -41.44%
Cash ROA snapshot only -36.48%
Cash ROIC snapshot only -32.52%
CROIC snapshot only -32.94%
NOPAT Margin snapshot only -23.86%
Pretax Margin snapshot only -27.46%
R&D / Revenue snapshot only 19.70%
SGA / Revenue snapshot only 11.44%
SBC / Revenue snapshot only 4.10%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -7.85 -8.19 -11.94 -8.77 -7.22 -7.05 -6.01 -4.94 -5.32 -8.47 -11.14 -14.37 -13.69 -14.73 -15.68 -9.51 -7.29 -9.27 -9.41 -7.62 -7.717
P/S Ratio 1191.98 248.82 210.74 206.82 207.99 202.04 202.32 357.79 595.33 1714.21 2555.07 3939.03 4502.49 4108.74 1937.81 2556.39 568.91 209.25 214.743
P/B Ratio 4.14 4.77 3.87 3.15 2.95 3.18 3.11 2.74 3.09 5.34 4.43 6.28 6.56 7.59 3.53 2.36 2.04 2.96 4.41 3.81 2.991
P/FCF -9.40 -9.83 -14.43 -12.70 -10.77 -10.12 -8.43 -6.01 -6.06 -10.12 -13.97 -18.35 -18.92 -20.11 -20.36 -11.77 -8.82 -11.02 -11.41 -9.01 -9.012
P/OCF
EV/EBITDA -6.02 -6.55 -8.94 -6.09 -4.82 -4.83 -3.92 -2.95 -3.39 -6.58 -8.50 -11.65 -10.98 -11.78 -10.04 -4.87 -3.32 -5.53 -6.63 -5.17 -5.173
EV/Revenue 885.27 170.27 139.61 142.06 138.04 124.72 133.78 287.62 469.03 1457.46 2189.13 3451.23 3249.03 2395.12 1002.21 1707.95 441.66 155.05 155.046
EV/EBIT -5.96 -6.49 -8.86 -6.04 -4.79 -4.80 -3.90 -2.94 -3.37 -6.54 -8.46 -11.59 -10.91 -11.69 -9.96 -4.83 -3.30 -5.49 -6.58 -5.13 -5.133
EV/FCF -7.15 -7.79 -10.72 -8.69 -7.13 -6.95 -5.60 -3.71 -4.01 -8.13 -11.01 -15.60 -16.21 -17.62 -14.69 -6.86 -4.56 -7.36 -8.86 -6.68 -6.678
Earnings Yield -12.7% -12.2% -8.4% -11.4% -13.8% -14.2% -16.6% -20.2% -18.8% -11.8% -9.0% -7.0% -7.3% -6.8% -6.4% -10.5% -13.7% -10.8% -10.6% -13.1% -13.13%
FCF Yield -10.6% -10.2% -6.9% -7.9% -9.3% -9.9% -11.9% -16.6% -16.5% -9.9% -7.2% -5.5% -5.3% -5.0% -4.9% -8.5% -11.3% -9.1% -8.8% -11.1% -11.10%
PEG Ratio snapshot only 0.279
Price/Tangible Book snapshot only 3.811
EV/Gross Profit snapshot only 156.781
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 16.92 16.92 21.55 21.55 21.55 21.55 12.45 12.45 12.45 12.45 13.07 13.07 13.07 13.07 23.04 23.04 23.04 23.04 12.32 12.32 12.323
Quick Ratio 16.92 16.92 21.55 21.55 21.55 21.55 12.45 12.45 12.45 12.45 13.07 13.07 13.07 13.07 23.04 23.04 23.04 23.04 12.30 12.30 12.299
Debt/Equity 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.10 0.10 0.10 0.10 0.04 0.04 0.04 0.04 0.05 0.05 0.049
Net Debt/Equity -0.99 -0.99 -1.00 -1.00 -1.00 -1.00 -1.05 -1.05 -1.05 -1.05 -0.94 -0.94 -0.94 -0.94 -0.98 -0.98 -0.98 -0.98 -0.99 -0.99 -0.987
Debt/Assets 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.08 0.08 0.08 0.08 0.04 0.04 0.04 0.04 0.04 0.04 0.043
Debt/EBITDA -0.05 -0.04 -0.03 -0.03 -0.02 -0.02 -0.02 -0.02 -0.02 -0.01 -0.23 -0.21 -0.19 -0.17 -0.15 -0.14 -0.12 -0.11 -0.09 -0.09 -0.090
Net Debt/EBITDA 1.89 1.71 3.10 2.81 2.46 2.20 1.99 1.83 1.74 1.61 2.29 2.05 1.84 1.66 3.88 3.49 3.10 2.75 1.91 1.81 1.808
Interest Coverage
Equity Multiplier 1.09 1.09 1.06 1.06 1.06 1.06 1.11 1.11 1.11 1.11 1.18 1.18 1.18 1.18 1.08 1.08 1.08 1.08 1.14 1.14 1.145
Cash Ratio snapshot only 12.083
Cash to Debt snapshot only 21.176
FCF to Debt snapshot only -8.643
Defensive Interval snapshot only 666.1 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.00 0.00 0.00 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.014
Inventory Turnover 0.00 0.20 0.198
Receivables Turnover 0.00 0.00 0.56 2.18 2.41 2.64 2.13 1.92 2.17 2.12 0.68 0.34 0.24 0.18 0.12 0.09 0.16 0.17 1.70 3.99 3.988
Payables Turnover 0.00 0.00 7.12 15.30 24.85 34.11 25.27 27.26 28.74 31.04 18.35 12.62 6.57 0.04 0.00 0.00 0.00 0.00 0.00 0.01 0.014
DSO 654 167 152 138 172 190 168 172 536 1089 1552 2068 3130 4279 2336 2119 215 92 91.5 days
DIO 0 0 0 0 0 0 0 0 0 0 0 0 1845 1845.1 days
DPO 51 24 15 11 14 13 13 12 20 29 56 9356 25973 25973.4 days
Cash Conversion Cycle 603 144 137 127 157 176 155 160 516 1060 1496 -7287 -24037 -24036.8 days
Fixed Asset Turnover snapshot only 0.330
Operating Cycle snapshot only 1936.6 days
Cash Velocity snapshot only 0.018
Capital Intensity snapshot only 62.842
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue -1.0% 3.4% 1.8% 4.0% -7.5% -15.3% -53.9% -71.3% -78.0% -74.1% -61.5% 0.5% 47.7% 6.4% 22.8% 22.77%
Net Income -41.6% -47.6% -45.8% -50.4% -52.5% -52.0% -52.3% -46.8% -35.6% -33.2% -30.9% -34.3% -40.6% -39.4% -39.1% -39.4% -43.0% -52.2% -55.9% -51.2% -51.22%
EPS -20.0% -26.7% -6.2% -4.1% -7.6% -8.3% -27.9% -30.0% -31.2% -26.1% -4.9% -0.2% 3.4% 1.2% -2.1% -8.2% -20.5% -29.4% -51.7% -35.2% -35.25%
FCF -34.6% -37.4% -43.1% -17.6% -22.3% -27.1% -31.3% -74.6% -77.4% -60.1% -46.3% -28.1% -15.9% -21.9% -34.4% -43.8% -63.4% -74.9% -67.0% -58.1% -58.12%
EBITDA -37.5% -44.9% -44.3% -48.7% -52.4% -53.8% -56.3% -53.8% -41.8% -37.3% -32.7% -36.4% -44.7% -47.5% -51.7% -51.3% -51.9% -55.7% -52.6% -45.0% -45.01%
Op. Income -37.0% -44.2% -43.7% -48.1% -51.9% -53.4% -55.9% -53.5% -41.6% -37.2% -32.6% -36.3% -44.8% -47.8% -52.2% -51.8% -52.2% -55.8% -52.5% -44.9% -44.86%
OCF Growth snapshot only -58.34%
Asset Growth snapshot only -20.85%
Equity Growth snapshot only -25.11%
Debt Growth snapshot only -6.15%
Shares Change snapshot only 11.81%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y -6.7% 35.4% 39.9% 45.6% 75.8% 1.0% 1.1% -1.2% -43.5% -33.1% -33.0% 17.6% 61.6% 61.56%
Revenue 5Y 53.8% 24.7% 3.1% -4.0% -8.9% 3.6% 8.5% 22.5%
EPS 3Y
EPS 5Y
Net Income 3Y
Net Income 5Y
EBITDA 3Y
EBITDA 5Y
Gross Profit 3Y
Gross Profit 5Y
Op. Income 3Y
Op. Income 5Y
FCF 3Y
FCF 5Y
OCF 3Y
OCF 5Y
Assets 3Y 1.3% 27.0% 27.0% 27.0% 27.0% 39.3% 39.3% 39.3% 39.3% 51.3% 51.3% 51.3% 51.3% 59.9% 59.9% 59.9% 59.9% 47.7% 47.7% 47.73%
Assets 5Y 86.5% 30.0% 30.0% 30.0% 30.0% 61.5% 61.5% 61.5% 61.5% 44.0% 44.0% 43.99%
Equity 3Y 39.3% 39.3% 39.3% 39.3% 47.2% 47.2% 47.2% 47.2% 58.6% 58.6% 58.6% 58.6% 46.4% 46.4% 46.38%
Book Value 3Y 6.7% 7.0% 16.0% 16.1% 16.1% 13.4% 14.4% 15.1% 25.4% 26.9% 30.7% 31.6% 21.5% 17.5% 17.55%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.95 0.30 0.13 0.23 0.27 0.31 0.61 0.75 0.77 0.56 0.49 0.16 0.09 0.06 0.11 0.00 0.00 0.01 0.41 0.43 0.428
Earnings Stability 1.00 0.99 0.99 0.99 0.97 0.98 0.97 0.97 0.98 0.98 0.98 0.97 0.96 0.96 0.96 0.95 0.95 0.93 0.92 0.93 0.930
Margin Stability 0.47 0.19 0.86 0.80 0.45 0.74 0.52 0.61 0.38 0.70 0.25 0.39 0.24 0.35 0.00 0.00 0.00 0.000
Rev. Growth Consistency 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 0.500
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.83 0.81 0.82 0.50 0.50 0.50 0.50 0.81 0.86 0.87 0.88 0.86 0.84 0.84 0.84 0.84 0.83 0.50 0.50 0.50 0.500
Earnings Smoothness
ROE Trend 0.11 0.13 0.12 0.13 -0.14 -0.14 -0.11 -0.11 0.02 0.02 0.02 0.03 0.23 0.25 0.25 0.25 -0.16 -0.16 -0.158
Gross Margin Trend -5.55 -20.26 -7.29 28.22 29.10 37.85 31.24 17.06 15.35 21.45 21.453
FCF Margin Trend 11.02 -66.84 -108.60 -168.02 -187.55 -285.58 -135.44 -116.29 82.04 198.05 198.053
Sustainable Growth Rate
Internal Growth Rate
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 0.83 0.83 0.82 0.69 0.66 0.69 0.70 0.81 0.87 0.82 0.78 0.76 0.70 0.72 0.76 0.80 0.81 0.83 0.81 0.83 0.834
FCF/OCF 1.01 1.01 1.00 1.00 1.01 1.01 1.01 1.01 1.01 1.02 1.03 1.03 1.04 1.02 1.02 1.01 1.02 1.02 1.02 1.01 1.013
FCF/Net Income snapshot only 0.845
CapEx/Revenue 40.4% 9.7% 18.5% 27.4% 35.0% 37.0% 25.0% 85.3% 1.2% 3.0% 4.9% 3.6% 3.7% 4.9% 4.3% 4.1% 74.9% 29.6% 29.57%
CapEx/Depreciation snapshot only 1.295
Accruals Ratio -0.10 -0.11 -0.07 -0.14 -0.17 -0.18 -0.14 -0.09 -0.07 -0.10 -0.10 -0.12 -0.16 -0.16 -0.07 -0.06 -0.07 -0.07 -0.07 -0.06 -0.064
Sloan Accruals snapshot only -0.277
Cash Flow Adequacy snapshot only -77.517
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio
FCF Payout Ratio
Total Payout Ratio
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -10.4% -10.9% -19.4% -24.0% -30.4% -26.8% -12.3% -13.8% -1.2% -20.2% -15.5% -22.2% -21.2% -11.1% -20.7% -18.9% -21.8% -14.2% -0.9% -11.3% -11.27%
Total Shareholder Return -10.4% -10.9% -19.4% -24.0% -30.4% -26.8% -12.3% -13.8% -1.2% -20.2% -15.5% -22.2% -21.2% -11.1% -20.7% -18.9% -21.8% -14.2% -0.9% -11.3% -11.27%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 1.00 1.00 1.00 1.01 1.00 0.99 0.98 0.96 0.96 0.96 0.96 0.95 0.93 0.91 0.88 0.87 0.87 0.89 0.90 0.91 0.909
EBIT Margin -99.91 -28.18 -29.17 -29.61 -35.44 -42.48 -39.72 -43.94 -55.47 -125.71 -200.68 -295.25 -326.13 -495.70 -303.92 -311.30 -67.15 -30.20 -30.203
Asset Turnover 0.00 0.00 0.00 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.014
Equity Multiplier 1.10 1.10 1.07 1.07 1.07 1.07 1.08 1.08 1.08 1.08 1.15 1.15 1.15 1.15 1.11 1.11 1.11 1.11 1.11 1.11 1.109
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-2.40 $-2.57 $-2.38 $-2.50 $-2.58 $-2.78 $-3.04 $-3.25 $-3.39 $-3.51 $-3.19 $-3.26 $-3.27 $-3.47 $-3.26 $-3.53 $-3.94 $-4.49 $-4.95 $-4.77 $-4.77
Book Value/Share $4.56 $4.41 $7.34 $6.96 $6.32 $6.17 $5.88 $5.87 $5.83 $5.57 $8.03 $7.46 $6.82 $6.73 $14.48 $14.23 $14.13 $14.06 $10.55 $9.53 $12.30
Tangible Book/Share $4.56 $4.41 $7.34 $6.96 $6.32 $6.17 $5.88 $5.87 $5.83 $5.57 $8.03 $7.46 $6.82 $6.73 $14.48 $14.23 $14.13 $14.06 $10.55 $9.53 $9.53
Revenue/Share $0.00 $0.00 $0.02 $0.09 $0.09 $0.09 $0.09 $0.08 $0.09 $0.08 $0.06 $0.03 $0.02 $0.01 $0.01 $0.01 $0.01 $0.02 $0.08 $0.17 $0.17
FCF/Share $-2.01 $-2.14 $-1.97 $-1.73 $-1.73 $-1.94 $-2.17 $-2.67 $-2.97 $-2.94 $-2.55 $-2.55 $-2.37 $-2.54 $-2.51 $-2.85 $-3.26 $-3.78 $-4.08 $-4.03 $-4.03
OCF/Share $-2.00 $-2.13 $-1.96 $-1.72 $-1.72 $-1.91 $-2.14 $-2.64 $-2.95 $-2.87 $-2.48 $-2.47 $-2.28 $-2.49 $-2.47 $-2.81 $-3.20 $-3.71 $-4.02 $-3.98 $-3.98
Cash/Share $4.61 $4.46 $7.38 $6.99 $6.35 $6.21 $6.21 $6.20 $6.16 $5.89 $8.32 $7.73 $7.07 $6.97 $14.80 $14.54 $14.44 $14.37 $10.93 $9.87 $12.40
EBITDA/Share $-2.38 $-2.55 $-2.36 $-2.47 $-2.56 $-2.79 $-3.10 $-3.36 $-3.52 $-3.63 $-3.30 $-3.42 $-3.50 $-3.80 $-3.67 $-4.01 $-4.47 $-5.03 $-5.45 $-5.20 $-5.20
Debt/Share $0.11 $0.10 $0.07 $0.06 $0.06 $0.06 $0.06 $0.06 $0.06 $0.05 $0.77 $0.72 $0.65 $0.65 $0.57 $0.56 $0.55 $0.55 $0.52 $0.47 $0.47
Net Debt/Share $-4.50 $-4.36 $-7.31 $-6.93 $-6.30 $-6.15 $-6.15 $-6.15 $-6.11 $-5.83 $-7.55 $-7.01 $-6.41 $-6.33 $-14.23 $-13.99 $-13.89 $-13.82 $-10.41 $-9.41 $-9.41
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 13.518
Altman Z-Prime snapshot only 25.947
Piotroski F-Score 3 3 4 4 4 4 3 3 4 2 4 5 4 4 4 4 4 4 2 2 2
Beneish M-Score -3.10 -2.89 -1.48 -2.90 1.87 -17.90 -2.93 -1.90 26.13 26.130
Ohlson O-Score snapshot only -3.539
ROIC (Greenblatt) snapshot only -53.61%
Net-Net WC snapshot only $8.69
EVA snapshot only $-432409680.00
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only A+
Credit Score 74.02 73.71 74.12 74.77 75.45 75.48 76.78 76.20 76.41 76.48 76.71 76.44 76.56 76.30 76.29 76.25 76.42 76.04 76.15 75.61 75.608
Credit Grade snapshot only 5
Credit Trend snapshot only -0.641
Implied Spread (bps) snapshot only 125.000
Industry Credit Rank snapshot only 76
Sector Credit Rank snapshot only 70

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms